AXL and hepatocellular carcinoma: Using a number of readouts of cell proliferation, motility and invasion capacity, we have shown that therapeutic modulation of Axl by genetic down-regulation as well as pharmacologic inhibition by R428, a well-characterised TKI with selective Axl-inhibitory properties,34 affects a wide range of hallmarks underlying the progression of HCC.